OverviewSuggest Edit
Humanigen (formerly known as KaloBios) is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. The Company's focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Its lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment.
| Type | Public | |
| Founded | 2000 | |
| HQ | Burlingame, CA, US | Map |
| Website | humanigen.com |
Recent NewsAll News
- Thinking about buying stock in Palantir Technologies, Super League Gaming, Phunware, Humanigen, or BioXcel Therapeutics?
- Thinking about buying stock in Humanigen, Marathon Oil, KemPharm, GoHealth, or SRAX Inc?
- Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
- Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug
Key People/Management at Humanigen
Cameron Durrant
Chairman & CEO
Bob Atwill
SVP, Head of Asia-Pacific Region
Dale Chappell
Chief Scientific Officer
Edward P. Jordan
Chief Commercial Officer
Omar Ahmed
SVP. Clinical, Medical and Scientific Affairs
Timothy Morris
Chief Operating and Financial Officer
Humanigen Office Locations
Humanigen has offices in Burlingame and Kansas City
Burlingame, CA, US (HQ)
533 Airport Blvd #400
Kansas City, MO, US
900 W 48th Pl #900, Kansas City
Humanigen Financials and Metrics
Humanigen Revenue
Humanigen's revenue was reported to be $312 k in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 312.0k |
Net income (FY, 2020) | (89.5m) |
EBIT (FY, 2020) | (88.2m) |
Market capitalization (30-Mar-2021) | 1.2b |
Closing stock price (30-Mar-2021) | 21.7 |
Cash (31-Dec-2020) | 67.7m |
Humanigen's current market capitalization is $1.2 b.
Annual
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.2m | 2.5m | 2.5m | 2.4m | 1.5m | 2.0m | 4.0m | 2.0m | 1.8m | 1.9m | 1.7m | 1.5m | 1.4m | 2.0m |
R&D expense | 1.7m | 4.4m | 1.7m | 2.7m | 3.9m | 3.8m | 696.0k | 577.0k | 535.0k | 359.0k | 1.2m | 549.0k | 659.0k | 21.1m |
Operating expense total | 2.9m | 6.9m | 4.2m | 5.1m | 5.4m | 5.8m | 4.7m | 2.6m | 2.3m | 2.2m | 3.0m | 2.0m | 2.1m | 23.1m |
EBIT | (2.9m) | (6.9m) | (4.2m) | (5.1m) | (5.4m) | (5.8m) | (4.7m) | (2.6m) | (2.3m) | (2.2m) | (3.0m) | (2.0m) | (2.1m) | (23.1m) |
Annual
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.6m | 11.9m | 2.9m | 4.0m | 103.0k | 1.1m | 1.6m | 267.0k | 2.0m | 180.0k | 1.1m | 157.0k | 68.0k | 41.7m |
Prepaid Expenses | 1.7m | 1.3m | 1.8m | 1.7m | 1.5m | 1.2m | 838.0k | 665.0k | 504.0k | 479.0k | 425.0k | 366.0k | 293.0k | 770.0k |
Current Assets | 8.3m | 13.3m | 4.7m | 5.7m | 1.7m | 2.3m | 2.4m | 932.0k | 2.5m | 659.0k | 1.5m | 523.0k | 361.0k | 42.5m |
PP&E | 170.0k | 145.0k | 121.0k | 53.0k | 41.0k | 30.0k | 10.0k |
Annual
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (5.4m) | (17.4m) | (22.0m) | (5.5m) | (11.7m) | (18.9m) | (5.1m) | (7.8m) | (9.9m) | (2.5m) | (5.9m) | (8.3m) | (2.5m) | (26.5m) |
Depreciation and Amortization | 33.0k | 58.0k | 81.0k | 14.0k | 27.0k | 38.0k | 10.0k | 19.0k | 19.0k | |||||
Accounts Payable | 3.2m | 4.6m | 3.5m | (507.0k) | (434.0k) | 327.0k | (28.0k) | (88.0k) | (159.0k) | 592.0k | 717.0k | 1.1m | 860.0k | (2.9m) |
Cash From Operating Activities | (2.0m) | (9.0m) | (17.9m) | (4.4m) | (8.3m) | (12.3m) | (1.8m) | (3.7m) | (5.0m) | (684.0k) | (2.3m) | (3.5m) | (607.0k) | (22.6m) |
| USD | FY, 2015 |
|---|---|
Financial Leverage | 1.9 x |
Humanigen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Celscia Therapeutics | ||
| KaloBios |
Humanigen Cybersecurity Score
Humanigen Online and Social Media Presence
Humanigen's Trends
Humanigen News and Updates
March 12, 2021
Thinking about buying stock in Palantir Technologies, Super League Gaming, Phunware, Humanigen, or BioXcel Therapeutics?
New York, March 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SLGG, PHUN, HGEN, and BTAI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...
March 05, 2021
Thinking about buying stock in Humanigen, Marathon Oil, KemPharm, GoHealth, or SRAX Inc?
NEW YORK, March 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, MRO, KMPH, GOCO, and SRAX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
February 03, 2021
Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
BURLINGAME, Calif. and TUSTIN, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for len…
January 25, 2021
Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug
Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 treatment. Emergent's stock was down 1.7%. The investigational therapy, lenzilumab, is currently being tested …
May 31, 2019
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- -- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 --
March 21, 2019
Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy
BURLINGAME, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (OTCQB: HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimization and immuno-oncolo…
Humanigen Frequently Asked Questions
When was Humanigen founded?
Humanigen was founded in 2000.
Who are Humanigen key executives?
Humanigen's key executives are Cameron Durrant, Bob Atwill and Dale Chappell.
How many employees does Humanigen have?
Humanigen has 2 employees.
What is Humanigen revenue?
Latest Humanigen annual revenue is $312 k.
What is Humanigen revenue per employee?
Latest Humanigen revenue per employee is $156 k.
Who are Humanigen competitors?
Competitors of Humanigen include Abcam, XOMA and MiracleCord.
Where is Humanigen headquarters?
Humanigen headquarters is located at 533 Airport Blvd #400, Burlingame.
Where are Humanigen offices?
Humanigen has offices in Burlingame and Kansas City.
How many offices does Humanigen have?
Humanigen has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies